Literature DB >> 22903962

Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups.

Santiago Ewig1, Torsten Bauer, Klaus Richter, Joachim Szenscenyi, Günther Heller, Richard Strauss, Tobias Welte.   

Abstract

C(U)RB-65 (confusion, (urea >7 mol · L(-1),) respiratory frequency ≥ 30 breaths · min(-1), systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg and age ≥ 65 years) is now the generally accepted severity score for patients with community-acquired pneumonia (CAP) in Europe. In an observational study based on the large database from the German nationwide performance measurement programme in healthcare quality, including data from all hospitalised patients with CAP during 2008-2010, different CRB-age groups (≥ 50 and ≥ 60 years) across the total CAP population and three entities of CAP (younger population aged <65 years, patients aged ≥ 65 years not residing in nursing homes and those with nursing home-acquired pneumonia (NHAP)) were validated for their potential to predict in-hospital death. 660 594 patients were investigated. Mortality was n=93 958 (14.0%). In the total population, CRB-80 had the optimal area under the curve (0.690, 95% CI 0.688-0.691). However, in the younger cohort, CRB-50 performed best (0.730, 95% CI 0.724-0.736), with good identification of low-risk patients (CRB-50 risk class 1: 1.28% deaths, negative predictive value 98.7%). In the elderly, CRB-80 as the optimal age group performed worse (0.663, 95% CI 0.660-0.655 in patients not residing in nursing homes; 0.608, 95% CI 0.605-0.611 in those with NHAP). In the latter group, all CRB-age groups failed to identify low-risk patients (CRB-80 risk class 1: 22.75% deaths, negative predictive value 81.8%). Patients with hospitalised CAP aged <65 years may be assessed by the CRB-50 score. In those aged ≥65 years (not NHAP) assessed by the CRB-65 score, low-risk patients are already are at an increased risk of death. In NHAP patients, even the use of CRB-80 does not identify low-risk patients and should be accompanied by the evaluation of functional status and comorbidity.

Entities:  

Mesh:

Year:  2012        PMID: 22903962     DOI: 10.1183/09031936.00065212

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Community-Acquired Pneumonia in Adults.

Authors:  Martin Kolditz; Santiago Ewig
Journal:  Dtsch Arztebl Int       Date:  2017-12-08       Impact factor: 5.594

Review 2.  Meta-analysis of Calibration, Discrimination, and Stratum-Specific Likelihood Ratios for the CRB-65 Score.

Authors:  Mark H Ebell; Mary E Walsh; Tom Fahey; Maggie Kearney; Christian Marchello
Journal:  J Gen Intern Med       Date:  2019-04-16       Impact factor: 5.128

Review 3.  [Risk scores for community acquired pneumonia in elderly and geriatric patients].

Authors:  M A Pflug; T Wesemann; H J Heppner; U Thiem
Journal:  Z Gerontol Geriatr       Date:  2015-05-09       Impact factor: 1.281

4.  Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry.

Authors:  Pedro David Wendel-Garcia; André Moser; Yok-Ai Que; Matthias Peter Hilty; Marie-Madlen Jeitziner; Hernán Aguirre-Bermeo; Pedro Arias-Sanchez; Janina Apolo; Ferran Roche-Campo; Diego Franch-Llasat; Gian-Reto Kleger; Claudia Schrag; Urs Pietsch; Miodrag Filipovic; Sascha David; Klaus Stahl; Souad Bouaoud; Amel Ouyahia; Patricia Fodor; Pascal Locher; Martin Siegemund; Nuria Zellweger; Sara Cereghetti; Peter Schott; Gianfilippo Gangitano; Maddalena Alessandra Wu; Mario Alfaro-Farias; Gerardo Vizmanos-Lamotte; Hatem Ksouri; Nadine Gehring; Emanuele Rezoagli; Fabrizio Turrini; Herminia Lozano-Gómez; Andrea Carsetti; Raquel Rodríguez-García; Bernd Yuen; Anja Baltussen Weber; Pedro Castro; Jesus Oscar Escos-Orta; Alexander Dullenkopf; Maria C Martín-Delgado; Theodoros Aslanidis; Marie-Helene Perez; Frank Hillgaertner; Samuele Ceruti; Marilene Franchitti Laurent; Julien Marrel; Riccardo Colombo; Marcus Laube; Alberto Fogagnolo; Michael Studhalter; Tobias Wengenmayer; Emiliano Gamberini; Christian Buerkle; Philipp K Buehler; Stefanie Keiser; Muhammed Elhadi; Jonathan Montomoli; Philippe Guerci; Thierry Fumeaux; Reto A Schuepbach; Stephan M Jakob
Journal:  Crit Care       Date:  2022-07-04       Impact factor: 19.334

5.  Validation of the CORB75 (confusion, oxygen saturation, respiratory rate, blood pressure, and age ≥ 75 years) as a simpler pneumonia severity rule.

Authors:  O Ochoa-Gondar; A Vila-Corcoles; T Rodriguez-Blanco; I Hospital; E Salsench; X Ansa; N Saun
Journal:  Infection       Date:  2013-11-29       Impact factor: 3.553

6.  External validation of the CURSI criteria (confusion, urea, respiratory rate and shock index) in adults hospitalised for community-acquired pneumonia.

Authors:  Harald Nüllmann; Marc Andre Pflug; Thomas Wesemann; Hans-Jürgen Heppner; Ludger Pientka; Ulrich Thiem
Journal:  BMC Infect Dis       Date:  2014-01-22       Impact factor: 3.090

7.  Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia.

Authors:  Ilija Andrijevic; Jovan Matijasevic; Ljiljana Andrijevic; Tomi Kovacevic; Bojan Zaric
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

Review 8.  Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.

Authors:  Dan Liu; Lixin Xie; Haiyan Zhao; Xueyao Liu; Jie Cao
Journal:  BMC Infect Dis       Date:  2016-05-26       Impact factor: 3.090

Review 9.  Major advances in managing community-acquired pneumonia.

Authors:  Waseem Asrar Khan; Mark Woodhead
Journal:  F1000Prime Rep       Date:  2013-10-01

10.  Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).

Authors:  Ilija Kuzman; Alexandr Bezlepko; Irena Kondova Topuzovska; László Rókusz; Liudmyla Iudina; Hans-Peter Marschall; Thomas Petri
Journal:  BMC Pulm Med       Date:  2014-06-30       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.